Table 3:

Main vaccines against canine leishmaniosis in South America and Europe (based on Solano-Gallego and others 2017)

Vaccine, manufacturer and country/region of licensingComposition of vaccineVaccine protocolAntibodies elicited by vaccineKinetics of antibodies at primary vaccination (peak and duration)Diagnostic interference associated with vaccine
Leish-Tec
Hertape Calier Sa├║de Animal
Brazil
Recombinant A2 antigen of Leishmania donovani; saponin adjuvantThree primary vaccination doses (subcutaneously) at 21-day intervals; one annual boosterAntibodies to A2 (and potentially to LPA)Peak: 21 days after the second dose of primary vaccination
Duration: decrease at six months
Detection of vaccinal antibodies with official ELISA
CaniLeish
Virbac
Europe
Purified LiESP; saponin-derived QA-21 adjuvantThree primary vaccination doses (subcutaneously) at 21-day intervals; one annual boosterAntibodies to LiESP and LPA (and potentially to Speed Leish K [Virbac] kinesins)Peak: two weeks after the third dose of primary vaccination
Duration: variable, but may persist for four to 12 months
Detection of vaccinal antibodies with quantitative tests (ELISA and IFAT); rare detection of vaccinal antibodies with Speed Leish K
Letifend
Laboratorios LETI
Europe
Recombinant chimeric protein Q (five antigenic fragments of four Leishmania infantum proteins [histone H2A, LiP2a, LiP2b, and LiPo]); no adjuvantOne primary vaccination dose (subcutaneous); one annual boosterAntibodies to protein QPeak: 14 days after primary vaccination
Duration: at least 60 days (not assessed beyond this)
No detection of vaccinal antibodies by quantitative tests (IFAT and ELISA) or rapid tests
  • IFAT Indirect fluorescent antibody test, LiESP Leishmania infantum excreted-secreted proteins, LPA Leishmania promastigote antigen